Biodexa completes recruitment of cohort a in study of mtx110 in patients with recurrent glioblastoma

Biodexa pharmaceuticals plc (“biodexa” or the “company”) biodexa completes recruitment of cohort a in study of mtx110 in patients with recurrent glioblastoma biodexa pharmaceuticals plc, (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, is pleased to announce that it has completed recruitment into cohort a of its ongoing phase 1 study of mtx110 (also known as magic-g1 study)(nct 05324501) in patients with recurrent glioblastoma (rgbm). magic-g1 is an open-label, dose escalation study designed to assess the feasibility and safety of intermittent infusions of mtx110 administered by convection enhanced delivery (ced) via implanted refillable pump and catheter.
BDRX Ratings Summary
BDRX Quant Ranking